, /PRNewswire/ — Target RWE, a leader in real-world evidence (RWE) solutions in liver disease and gastroenterology, shared the latest research derived from its metabolic dysfunction-associated steatohepatitis (MASH) and eosinophilic gastrointestinal diseases (EGIDs) patient cohorts at the American College of Gastroenterology (ACG) 2024 Annual Meeting. The insights offer a deeper understanding of disease characteristics, patient demographics, and treatment patterns in patients with MASH and EGIDs.
The MASH & EGIDs patient cohorts are integral to Target RWE’s observational studies in TARGET-LD and TARGET-GASTRO.
The MASH and EGIDs patient cohorts are integral to Target RWE’s extensive and comprehensive observational registries in liver disease (TARGET-LD) and gastroenterology (TARGET-GASTRO). TARGET-LD and TARGET-GASTRO have established a powerful solution that captures the entire patient journey in complex, intersecting disease areas including metabolic disorders (TARGET-METABOLIC). With more than 600,000 patients in TARGET-LD and 30,000 in TARGET-GASTRO and planned expansion, Target RWE is uniquely positioned to generate valuable real-world insights that drive clinical research and improve therapeutic approaches.
…